Ces Urol 2015, 19(1):33-43 | DOI: 10.48095/cccu2015004

Immunostimulation with polybacterial lysate (Urivac®) in preventing recurrent lower urinary tract infections

Miroslav Hanuš¹, Michaela Matoušková¹, Vlasta Králová¹, Jan Hiblbauer jr.², Jakub Szewczyk³, Radek Sýkora³, Riad Sabra⁴, Peter Tomaštík⁵, Jiří Paseka⁶

¹ Urocentrum, Praha

² Sanus, Hradec Hrálové

³ Urologické oddělení, FN Ostrava

⁴ Urolog, Praha

⁵ Urohelp, Brno

⁶ Leading Clinical Research

Penile cancer is rare tumour, however it has serious psychological and social consequences.
The incidence of penile cancer increases with reaching with maximum in the sixth decade of life. The aetiological and epidemiological penile cancer risk factors are well recognized. Among them human papilloma virus infection, namely types HPV 16 and 18 is an important. Due to its low incidence about 1/100 000, there is limited experience with penile cancer therapy in most of urology or oncology departments. Randomised prospective studies are not available. Reports about surgical and other oncological therapy describe small studies with patients treated during long period. Early surgical treatment of penile lesions, and if possible of nodal metastases, plays an essential role in curing the disease and its prognosis. The review article highlights the importance of precise diagnosis and staging for the stratification of the patients and selection appropriate therapy according to risk and prognostic factors. The role of contemporary radiotherapy and chemotherapy in multimodal treatment of penile cancer is discussed. Additionally, personal experience with HDR brachytherapy in the treatment of 25 patients is discussed.

Keywords: Immunomodulatory therapy, bacterial lysate, recurrent urinary tract infection (RUTI).

Published: April 20, 2015